Recently, two new drugs, sotorasib (Lumakras) [179] and adagrasib (Krazati) [180], have been approved to treat people with non-small cell lung cancer that has the KRAS G12C mutation, and those in development include MRTX1133 targeting KRAS G12D mutations. Here, KRAS is linked to non-small cell lung carcinoma.